Synthetic Biology Industry Innovation and Development Forum | Empowering Innovation and Unlocking Potential

In 2022, the synthetic biology industry entered a growth phase. Its momentum not only spread from the United States to China but also extended from the secondary market to the primary market, with total financing reaching record highs and significant market potential. Among various downstream pharmaceutical sectors, synthetic biology has made positive progress in areas such as drug synthesis, medical aesthetics, and innovative therapies.

The 7th Future Healthcare 100 Conference, in collaboration with Hengxu Capital, will host the Forum on Innovative Development of the Synthetic Biology Industry. The forum will invite guests from industry, academia, and investment sectors to jointly discuss China’s synthetic biology technologies, industrial applications, development trends, and investment strategies, providing a platform for industry exchange and sharing to foster technological innovation and collaborative development across the supply chain in the healthcare field.

2023 Future Healthcare Top 100 Conference, co-hosted by VB100, VCBeat, and Eggshell Research Institute, with strategic partnership support from Shanghai Zhangjiang Group, will be grandly held at the Shanghai Zhangjiang Science Hall from May 5–7, 2023. Led by Academician Robert Langer and IEEE scientists, nearly 500 industry luminaries will convene for three main forums and 31 trending thematic sessions.